FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046705094> ?p ?o ?g. }

• W2046705094 endingPage "5335" @default.
• W2046705094 startingPage "5328" @default.
• W2046705094 abstract "Both all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)) have proven to be very effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but they had not been used jointly in an integrated treatment protocol for remission induction or maintenance among newly diagnosed APL patients. In this study, 61 newly diagnosed APL subjects were randomized into three treatment groups, namely by ATRA, As(2)O(3), and the combination of the two drugs. CR was determined by hematological analysis, tumor burden was examined with real-time quantitative RT-PCR of the PML-RAR alpha (promyelocytic leukemia-retinoic acid receptor alpha) fusion transcripts, and side effects were evaluated by means of clinical examinations. Mechanisms possibly involved were also investigated with cellular and molecular biology methods. Although CR rates in three groups were all high (> or =90%), the time to achieve CR differed significantly, with that of the combination group being the shortest one. Earlier recovery of platelet count was also found in this group. The disease burden as reflected by fold change of PML-RAR alpha transcripts at CR decreased more significantly in combined therapy as compared with ATRA or As(2)O(3) mono-therapy (P < 0.01). This difference persisted after consolidation (P < 0.05). Importantly, all 20 cases in the combination group remained in CR whereas 7 of 37 cases treated with mono-therapy relapsed (P < 0.05) after a follow-up of 8-30 months (median: 18 months). Synergism of ATRA and As(2)O(3) on apoptosis and degradation of PML-RAR alpha oncoprotein might provide a plausible explanation for superior efficacy of combination therapy in clinic. In conclusion, the ATRA/As(2)O(3) combination for remission/maintenance therapy of APL brings much better results than either of the two drugs used alone in terms of the quality of CR and the status of the disease-free survival." @default.
• W2046705094 created "2016-06-24" @default.
• W2046705094 creator A5003886138 @default.
• W2046705094 creator A5009658768 @default.
• W2046705094 creator A5021134430 @default.
• W2046705094 creator A5025570473 @default.
• W2046705094 creator A5044277083 @default.
• W2046705094 creator A5048693408 @default.
• W2046705094 creator A5048988662 @default.
• W2046705094 creator A5055305708 @default.
• W2046705094 creator A5061648551 @default.
• W2046705094 creator A5065018805 @default.
• W2046705094 creator A5073803028 @default.
• W2046705094 creator A5077066897 @default.
• W2046705094 creator A5086200936 @default.
• W2046705094 creator A5086332136 @default.
• W2046705094 creator A5089555790 @default.
• W2046705094 creator A5090253956 @default.
• W2046705094 creator A5090495842 @default.
• W2046705094 creator A5091381371 @default.
• W2046705094 date "2004-03-24" @default.
• W2046705094 modified "2023-10-14" @default.
• W2046705094 title "<i>All-trans</i> retinoic acid/As ₂ O ₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia" @default.
• W2046705094 cites W130028085 @default.
• W2046705094 cites W1486948598 @default.
• W2046705094 cites W1516721790 @default.
• W2046705094 cites W1541929695 @default.
• W2046705094 cites W1550565578 @default.
• W2046705094 cites W1554600230 @default.
• W2046705094 cites W1632166816 @default.
• W2046705094 cites W1692919389 @default.
• W2046705094 cites W1855965601 @default.
• W2046705094 cites W1909732837 @default.
• W2046705094 cites W192794212 @default.
• W2046705094 cites W1966102731 @default.
• W2046705094 cites W1966949577 @default.
• W2046705094 cites W1969288783 @default.
• W2046705094 cites W1970740283 @default.
• W2046705094 cites W1977662716 @default.
• W2046705094 cites W1979513962 @default.
• W2046705094 cites W1981986388 @default.
• W2046705094 cites W1992276338 @default.
• W2046705094 cites W2004046791 @default.
• W2046705094 cites W2007578289 @default.
• W2046705094 cites W2009774822 @default.
• W2046705094 cites W2011636814 @default.
• W2046705094 cites W2019057620 @default.
• W2046705094 cites W2042425638 @default.
• W2046705094 cites W2063759625 @default.
• W2046705094 cites W2068876833 @default.
• W2046705094 cites W2079526924 @default.
• W2046705094 cites W2101730597 @default.
• W2046705094 cites W2103728018 @default.
• W2046705094 cites W2103962971 @default.
• W2046705094 cites W2107954651 @default.
• W2046705094 cites W2108362314 @default.
• W2046705094 cites W2125549690 @default.
• W2046705094 cites W2128291738 @default.
• W2046705094 cites W2133935930 @default.
• W2046705094 cites W2138347314 @default.
• W2046705094 cites W2142423276 @default.
• W2046705094 cites W2146907085 @default.
• W2046705094 cites W2147505659 @default.
• W2046705094 cites W2151347057 @default.
• W2046705094 cites W2167805334 @default.
• W2046705094 cites W2224360281 @default.
• W2046705094 cites W2242790540 @default.
• W2046705094 cites W2290042519 @default.
• W2046705094 cites W2314037093 @default.
• W2046705094 cites W2327237185 @default.
• W2046705094 cites W2334200141 @default.
• W2046705094 cites W2395540659 @default.
• W2046705094 cites W2396425822 @default.
• W2046705094 cites W2407345634 @default.
• W2046705094 cites W2415250611 @default.
• W2046705094 cites W4255479410 @default.
• W2046705094 cites W432680243 @default.
• W2046705094 cites W92934419 @default.
• W2046705094 doi "https://doi.org/10.1073/pnas.0400053101" @default.
• W2046705094 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/397380" @default.
• W2046705094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15044693" @default.
• W2046705094 hasPublicationYear "2004" @default.
• W2046705094 type Work @default.
• W2046705094 sameAs 2046705094 @default.
• W2046705094 citedByCount "550" @default.
• W2046705094 countsByYear W20467050942012 @default.
• W2046705094 countsByYear W20467050942013 @default.
• W2046705094 countsByYear W20467050942014 @default.
• W2046705094 countsByYear W20467050942015 @default.
• W2046705094 countsByYear W20467050942016 @default.
• W2046705094 countsByYear W20467050942017 @default.
• W2046705094 countsByYear W20467050942018 @default.
• W2046705094 countsByYear W20467050942019 @default.
• W2046705094 countsByYear W20467050942020 @default.
• W2046705094 countsByYear W20467050942021 @default.
• W2046705094 countsByYear W20467050942022 @default.
• W2046705094 countsByYear W20467050942023 @default.
• W2046705094 crossrefType "journal-article" @default.

• next